Aztar (AZR) Financials

Data-quality note: The supplied statements identify the company as Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), not Aztar (NASDAQ: AZR). The analysis below therefore reflects the financial data provided for ADIL and should not be attributed to Aztar without confirming the ticker and source.

Based on the provided statements, the company remains a pre-revenue development-stage business. Reported revenue was $0 in each of the available income statements, while operating losses continued throughout the period.

• Cash position improved sharply in Q2 2026. Cash and equivalents increased from $4.6 million at March 31, 2026, to $28.7 million at June 30, 2026. The company also reported a $24.1 million net increase in cash during the quarter.
• Near-term liquidity is stronger than at the beginning of 2026. Total current assets reached $28.8 million versus $5.1 million of current liabilities, implying a current ratio of approximately 5.6 at the end of Q2 2026.
• Financing activity provided substantial capital. Q2 2026 financing cash flow was $25.2 million, including $27.6 million from common-equity issuance. This funding reduced the immediate risk of a cash shortfall.
• Investing cash flow was a source of liquidity in Q2. The company reported $5.3 million of net cash from investing activities, which also helped offset operating cash consumption during the quarter.
• Operating cash burn has historically been persistent but relatively consistent before Q2 2026. Operating cash outflows were $1.6 million in Q1 2026, $1.3 million in Q4 2025, $1.8 million in Q3 2025, and between $1.5 million and $2.1 million in the available 2024 quarters.
• The Q2 2026 cash flow statement contains unusually large non-cash adjustments. Non-cash adjustments totaled $46.3 million, offsetting most of the $52.0 million net loss and producing operating cash flow of negative $6.4 million. Investors should review the underlying filing to understand the nature and durability of these adjustments.
• Losses expanded dramatically in Q2 2026. Net loss increased to $52.0 million from $2.0 million in Q1 2026. Research and development expense surged to $46.6 million from $432,530, while selling, general and administrative expense increased to $5.4 million from $1.6 million.
• The company has not demonstrated revenue generation. Zero revenue was reported in the available quarters, leaving the business dependent on equity financing, other financing sources and asset transactions to fund operations.
• Equity financing has created substantial dilution risk. Weighted-average basic shares increased from 261,590 in Q1 2024 to 4.62 million in Q2 2026, with particularly large increases during 2025 and 2026. Additional capital raises could further dilute existing shareholders.
• Equity quality deteriorated materially by June 30, 2026. Total liabilities were $28.9 million, while common equity was negative $38.4 million. The balance sheet also included $38.5 million of redeemable noncontrolling interest and $23.8 million of other noncurrent operating liabilities, making the reported cash balance less representative of shareholder value than it would be for a mature, profitable company.

Overall, the latest quarter shows improved cash availability but a much weaker operating result. The company’s immediate liquidity benefited from financing and investing inflows rather than from its operations. For investors, the most important issues to monitor are whether the Q2 2026 expense spike is recurring, how quickly cash is consumed in subsequent quarters, the terms of future financing, and whether the company can begin generating revenue.